Browsing Tag
BofA Securities
11 posts
Suja Life files for Nasdaq IPO as better-for-you beverage growth meets public market scrutiny
Suja Life has filed for a Nasdaq IPO. Read why its growth, debt load, brand mix, and category timing matter more than the filing itself.
ICICIBANK at Rs 1,310: 38 analysts say buy. April 18 decides.
ICICI Bank (NSE: ICICIBANK) Q4 FY26 results on April 18. PAT consensus ₹11,500 to 12,200 Cr. Analyst targets up to ₹2,040. Key risks, iMobile Pay, and dividend outlook covered.
A $560m test for the diabetes device market as MiniMed prepares to trade on Nasdaq
MiniMed prices its IPO at $20 per share, raising $560M as Medtronic plc spins out its diabetes unit. Discover what the move means for the diabetes technology market.
Sealed Air Corporation (NYSE: SEE) wins stockholder approval for $10.3bn acquisition by CD&R
Sealed Air Corporation wins stockholder approval for its $10.3B CD&R buyout. Discover what this means for packaging markets and investors. Read more.
Lilly to acquire Ventyx Biosciences (Nasdaq: VTYX) in a high-conviction bet on oral inflammation therapies
Eli Lilly is acquiring Ventyx Biosciences for $1.2B to advance oral inflammation therapies. Find out what this means for biotech M&A and chronic care strategy.
Globus Medical to expand into pain management with Nevro acquisition
Globus Medical, Inc., a global leader in musculoskeletal solutions headquartered in Audubon, Pennsylvania, has entered into a definitive…
Keurig Dr Pepper bets $990m on GHOST—Is this the energy drink shake-up we’ve been waiting for?
Keurig Dr Pepper (NASDAQ: KDP) has announced a $990 million agreement to acquire a 60% stake in the…
Ceribell’s stock surges 36% in blockbuster trading debut: AI seizure tech takes Wall Street by storm
In a sensational opening on Wall Street, Ceribell’s stock surged by 36% in its trading debut, reflecting immense…
Biotech stocks in trouble? Immatics shares plunge after $150m funding news shocks investors
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has seen its shares decline significantly…
Blue Owl Capital announces strategic merger with Blue Owl Capital III
Blue Owl Capital Corporation has entered into a definitive merger agreement with Blue Owl Capital Corporation III. This…